Background: It is known that one of the features of rheumatoid arthritis (RA) is a generalized bone loss, therefore important tasks for the physician are timely evaluating of the risk of fractures and approving osteoporosis treatment in patients with RA.
Objectives: Through the Programme of the Russian Association of Rheumatology for the diagnosis, prevention and treatment osteoporosis (OP) in patients with RA we evaluated the 10 year probability of major osteoporotic fracture by FRAX for Russia in patients with RA, and we identified prevalence osteoporosis treatment in patients with high or low risk of osteoporotic fractures (OF).
Material and methods: Through the Programme of a large amount of patients with RA from 12 clinical centers in Russia 534 patients aged 41 89 years were selected and have been evaluated the risk of OF by FRAX.
Results: 459 (86%) women and 75 (14%) men were involved in our study. Female average age was 60.85 years, male one was 60.1 years. OP was diagnosed in 88 (16%) patients, 61 (11%) had a history of OF, however, of these people OP treatment was approved only 80 (91%) and 31 (51%) respectively. 168 (31%) patients had indications to approve OP treatment, defined using FRAX, only 51 (30%) of these people treatment was imposed. Assignment of treatment didnt need for 366 (69%) patients, however treatment was approved 45 (12%) from them. 65 (68%) patients were taking prescribed medications, 42 (65%) of them bisphosphonates plus calcium and/or vitamin D supplementation, 14 (21%) calcium and vitamin D, 9 (14%) calcitonin.
Conclusion: Osteoporosis management is not quite enough in patients with RA in Russia. There is substantial variation in the quality of risk evaluation of the osteoporotic fractures and treatment. Introduction of FRAX for allocation of group of patients with RA with a high risk of fracture will contribute to a personalized approach to approving treatment.